A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma

Category Primary study
JournalCANCER RESEARCH
Year 2017
This article has no abstract
Epistemonikos ID: 7a3ce19b12c99bc9455a82f92e2e1f539eaaf95c
First added on: Feb 08, 2025